Literature DB >> 3006960

Osteonecrosis of bone associated with combination chemotherapy without corticosteroids.

J V Marymont, E E Kaufman.   

Abstract

Osteonecrosis (aseptic or avascular necrosis of bone) is an entity with many causes that can occur at a variety of sites. It is a known complication of corticosteroid therapy, either alone or combined with other drugs in the treatment of malignancy. Osteonecrosis associated with chemotherapy that does not include corticosteroids is rare; three such cases have been reported in the English literature. One received cyclophosphamide alone, another vinblastine and bleomycin, while the third received cyclophosphamide, methotrexate, and 5-fluorouracil. The authors report a 40-year-old woman who had a left radical mastectomy in 1978 and a right radical mastectomy in 1980 for infiltrating ductal adenocarcinoma of the breasts. She received melphalan following the first surgery and a combination of doxorubicin, cyclophosphamide, and 5-fluorouracil after the second operation. In 1984 she noted pain in both knees that slowly increased in severity. A bone scan revealed increased periarticular activity in the medial and lateral femoral condyles of both knees compatible with bilateral osteonecrosis. There was no evidence of metastatic carcinoma on the bone scan. The patient was treated surgically with drilling and autologous bone grafting. A bone biopsy at the time of surgery revealed osteonecrosis but no metastatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3006960

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  6 in total

Review 1.  Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

Review 2.  Potential pathophysiological mechanisms in osteonecrosis of the jaw.

Authors:  Regina Landesberg; Victoria Woo; Serge Cremers; Matthew Cozin; Darja Marolt; Gordana Vunjak-Novakovic; Stavroula Kousteni; Srikala Raghavan
Journal:  Ann N Y Acad Sci       Date:  2011-02       Impact factor: 5.691

3.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.

Authors:  J Calvo-Alén; G McGwin; S Toloza; M Fernández; J M Roseman; H M Bastian; E J Cepeda; E B González; B A Baethge; B J Fessler; L M Vilá; J D Reveille; G S Alarcón
Journal:  Ann Rheum Dis       Date:  2005-11-03       Impact factor: 19.103

4.  Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Authors:  Jeanny B Aragon-Ching; Yang-Min Ning; Clara C Chen; Lea Latham; Jean-Pierre Guadagnini; James L Gulley; Philip M Arlen; John J Wright; Howard Parnes; William D Figg; William L Dahut
Journal:  Cancer Invest       Date:  2009-02       Impact factor: 2.176

Review 5.  Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review.

Authors:  Katharine Shim; Mary J MacKenzie; Eric Winquist
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Case report 669: Osteonecrosis of bone associated with intraarterial therapy using cisplatin.

Authors:  P Wuisman; R Erlemann; A Roessner; A Bosse; C Kusniez-Glaz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.